Real-world study checks if luspatercept cuts transfusions for MDS patients in china
NCT ID NCT07073690
First seen May 19, 2026 · Last updated Jun 22, 2026 · Updated 6 times
Summary
This completed study looked at 88 adults in China with lower-risk myelodysplastic syndromes (MDS) who had not received prior ESA therapy. Researchers tracked how often patients needed red blood cell transfusions and whether their hemoglobin levels improved while taking luspatercept. The goal was to see how the drug performs in real-world settings, outside of strict clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Zhijian Xiao
Tianjin, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
luspatercept
What this could lead to
If results are positive, this could confirm that luspatercept helps lower-risk MDS patients need fewer blood transfusions and maintain healthier hemoglobin levels.
What could go wrong
This is a small, completed real-world study, not a large controlled trial. Results may not apply to all patients, and the drug may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.